Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 202

The DOI matches its Crossref record.

The evolution of drug–resistant malaria: the role of drug elimination half–life

Open access
Hastings, Ian M., Watkins, William M., White, Nicholas J.·2002·Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences

Abstract

This paper seeks to define and quantify the influence of drug elimination half–life on the evolution of antimalarial drug resistance. There are assumed to be three general classes of susceptibility of the malaria parasite Plasmodium falciparum to a drug: Res0 , the original, susceptible wildtype; Res1 , a group of intermediate levels of susceptibility that are more tolerant of the drug but still cleared by treatment; and Res2 , which is completely resistant to the drug. Res1 and Res2 resistance both evolve much faster if the antimalarial drug has a long half–life. We show that previous models have significantly underestimated the rate of evolution of Res2 resistance by omitting the effects of drug half–life. The methodology has been extended to investigate (i) the effects of using drugs in combination, particularly when the components have differing half–lives, and (ii) the specific example of the development of resistance to the antimalarial pyrimethamine–sulphadoxine. An important detail of the model is the development of drug resistance in two separate phases. In phase A, Res1 is spreading and replacing the original sensitive forms while Res2 remains at a low level. Phase B starts once parasites are selected that can escape drug action ( Res1 genotypes with borderline chemosensitivity, and Res2 ): these parasites are rapidly selected, a process that leads to widespread clinical failure. Drug treatment is clinically successful during phase A, and health workers may be unaware of the substantial changes in parasite population genetic structure that predicate the onset of phase B. Surveillance programs are essential, following the introduction of a new drug, to monitor effectively changes in treatment efficacy and thus provide advance warning of drug failure. The model is also applicable to the evolution of antibiotic resistance in bacteria: in particular, the need for these models to incorporate drug pharmacokinetics to avoid potentially large errors in their predictions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1098/rstb.2001.1036

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 202

Metadata

Authors
Hastings, I. M., Watkins, W. M., & White, N. J.
Venue
Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences
Published
2002-04-29
Volume
357
Issue
1420
Pages
505-519
ISSN
  • 0962-8436 (ISSN-L)
  • 1471-2970
OpenAlex
W1990484067
Cited by
202
References
0
FWCI
14.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The evolution of drug–resistant malaria: the role of drug elimination half–life. https://app.cochat.ai/papers/10.1098/rstb.2001.1036
The paper
Hastings, I. M., Watkins, W. M., & White, N. J. (2002). The evolution of drug–resistant malaria: the role of drug elimination half–life. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences. https://doi.org/10.1098/rstb.2001.1036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.